

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN INSTITUTIONAL LLC and PFIZER INC.,  
Petitioners,

v.

NOVO NORDISK A/S,  
Patent Owner.

---

IPR2020-00324<sup>1</sup>  
Patent 8,114,833 B2

---

Before ERICA A. FRANKLIN, JOHN G. NEW, and  
SUSAN L. C. MITCHELL, *Administrative Patent Judges*.

FRANKLIN, *Administrative Patent Judge*.

ORDER  
Granting Petitioner Pfizer's Motion for Withdrawal  
and Substitution of Counsel  
*37 C.F.R. § 42.10*

---

<sup>1</sup> IPR2020-01252 has been joined with this proceeding.

Counsel may withdraw from an *inter partes* review proceeding only with authorization from the Board. 37 C.F.R. § 42.10(e). With authorization from the Board, Petitioner Pfizer Inc. (“Pfizer”) filed a motion for withdrawal and substitution of its current lead and back-up counsel. Paper 41 (“Mot.”). Specifically, Pfizer seeks to withdraw Jovial Wong, of Winston & Strawn LLP, as lead counsel, and Charles B. Klein and Sharon Lin, also of Winston & Strawn LLP, as back-up counsel.<sup>2</sup> *Id.* at 2. Pfizer seeks to substitute Thomas J. Meloro, of Willkie Farr & Gallagher LLP, as new lead counsel, and Michael W. Johnson, also of Willkie Farr & Gallagher LLP, as new back-up counsel. *Id.* at 1. Pfizer informs us that Co-Petitioner Mylan Institutional LLC and Patent Owner Novo Nordisk A/S do not oppose the motion. *Id.* at 1.

In accordance with 37 C.F.R. § 42.10(b), Pfizer filed an amended Power of Attorney, Paper 42, to reflect appointment of the proposed substitute counsel. Pfizer has also updated its Mandatory Notices to reflect the proposed substitute counsel. Paper 43.

#### ORDER

In consideration of the foregoing, it is hereby:

ORDERED that Pfizer’s Motion for Withdrawal and Substitution of Counsel is *granted*;

---

<sup>2</sup> Pfizer’s original mandatory notices identified Charles B. Klein as back-up counsel. IPR2020-01252, Paper 2, 2. However, Pfizer’s original power of attorney, IPR2020-01252, Paper 1, and Pfizer’s motion for withdrawal and substitution of counsel, Mot., identify him as lead counsel. Consistent with the original mandatory notices, we refer to him as back-up counsel in this Order.

IPR2020-00324  
Patent 8,114,833 B2

FURTHER ORDERED that Jovial Wong, Charles B. Klein, and Sharon Lin are no longer recognized as counsel for Pfizer in this proceeding; and

FURTHER ORDERED that Thomas J. Meloro is recognized as new lead counsel for Pfizer, and Michael W. Johnson is recognized as new back-up counsel for Pfizer.

For PETITIONER MYLAN:

Brandon White  
[White-ptab@perkinscoie.com](mailto:White-ptab@perkinscoie.com)

Lara Dueppen  
[Dueppen-ptab@perkinscoie.com](mailto:Dueppen-ptab@perkinscoie.com)

Emily Greb  
[Greb-ptab@perkinscoie.com](mailto:Greb-ptab@perkinscoie.com)

For PETITIONER PFIZER:

Thomas J. Meloro  
[tmeloro@willkie.com](mailto:tmeloro@willkie.com)

Michael W. Johnson  
[Mjohnson1@willkie.com](mailto:Mjohnson1@willkie.com)

For PATENT OWNER:

Jeffrey Oelke  
[joelke@fenwick.com](mailto:joelke@fenwick.com)

Ryan Johnson  
[Ryan.johnson@fenwick.com](mailto:Ryan.johnson@fenwick.com)

Laura Moran  
[Laura.moran@fenwick.com](mailto:Laura.moran@fenwick.com)